Dialysis Population Has Excess Cancer Mortality
Patients on dialysis die from cancer at twice the rate as those of the same age and sex in the general population, a study found.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
Second Primary Cancers Less Likely With IMRT vs CRT for Prostate Tumors
Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a reduced risk for second primary solid malignancies compared with 3D conformal RT.
Novel Agent N-803 Safe, Effective for BCG-Unresponsive High-Risk NMIBC
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
Adjuvant Everolimus Appears Beneficial in Very High-Risk Kidney Cancer
Everolimus improved recurrence-free survival in patients with very high-risk disease but not in those with intermediate high-risk disease.
Tislelizumab Shows Promise for High-Risk Nonmuscle-Invasive Bladder Cancer
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
Outcomes of Robotic, Open Cystectomy Compared in Bladder Cancer
The number of days alive and out of the hospital within the first 90 days of surgery is greater for robot-assisted surgery, but the clinical significance of the findings unclear.
Cancer Risks Increase With Albuminuria
In a Dutch study, each doubling of urine albumin excretion was significantly associated with a 7% increase in overall cancer risk.
Eponyms in Oncology: Von Hippel-Lindau Disease
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of von Hippel-Lindau disease.
Robotic Partial Nephrectomy Outcomes Worse When PSMs Are Present
Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
Neoadjuvant Axitinib May Enable Partial Nephrectomy in Complex Renal Tumors
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
Predictors of Recurrence After RNU for Low-Grade UTUC
The findings may inform surveillance strategies and improve treatment outcomes.
Black vs White Race Tied to Worse Survival in Renal Cell Carcinoma
While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.
Post-RC Radiation Does Not Up Survival in Locally Advanced Bladder Cancer
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
ICIs May Improve mRCC Outcomes in Cytoreductive Nephrectomy Cases
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
Use of 5-ARIs May Decrease Bladder Cancer Risk
A study examined bladder cancer risk and mortality among nearly 100,000 men from Ontario, Canada, who received 5-alpha reductase inhibitors.
UTUC in Octogenarians Frequently Managed Without Surgery
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.
Prostate, Bladder Cancer Care Delays Common During Pandemic
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
DNA Assay May Distinguish Responses to mRCC Immunotherapy
The TARDIS assay could be used to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...